Search the Newsreel

AnaptysBio (ANAB) awards CEO 53,334 performance stock units

AnaptysBio (ANAB) has awarded its President and CEO, Daniel Faga, 53,334 performance stock units (PSUs). These PSUs were granted after meeting specific performance criteria and will vest over two years, with 50% vesting on March 12, 2027, and the remaining 50% on March 12, …

AnaptysBio (NASDAQ: ANAB) awards 16,667 performance stock units to its CMO

AnaptysBio (NASDAQ: ANAB) has awarded 16,667 performance stock units (PSUs) to its Chief Medical Officer, Paul F. Lizzul. These PSUs were granted on March 12, 2026, after achieving certified performance criteria, with each unit representing a right to one share of common stock. The …

AnaptysBio Inc (ANAB) Stock News Today

AnaptysBio Inc (ANAB) Earnings Forecast: Future EPS & Revenue Growth Estimates

AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has received an average "Moderate Buy" rating from twelve brokerages, with an average 12-month price target of $82.00. Despite missing quarterly earnings per share estimates, the company exceeded revenue expectations. Several institutions have recently increased their holdings in AnaptysBio stock.

AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute

AnaptysBio (ANAB) has entered a key post-trial phase in its legal dispute with Tesaro and GlaxoSmithKline, involving allegations of material breach of contract and tortious interference. Following a trial in July 2026, a schedule for post-trial briefing and argument has been set, with key …

AnaptysBio and Tesaro set post-trial briefing schedule after July 2026 trial

AnaptysBio announced the post-trial briefing schedule following its July 2026 litigation with Tesaro and GlaxoSmithKline. A Joint Stipulation was granted by the Court, setting deadlines for briefs, with AnaptysBio filing its opening brief by August 21, 2026. Oral arguments are scheduled for October 20, …

AnaptysBio Inc (ANAB) Financial Health: Profitability & Balance Sheet Analysis

AnaptysBio Inc (ANAB) has a strong financial score of 7.86, placing it high within the Biotechnology & Medical Research industry, indicating robust financial health and high operating efficiency. Despite this, its latest quarterly revenue and net profit experienced year-over-year decreases of 7.98% and 34.47% …

AnaptysBio-Tesaro trial heads to post-trial briefs, argument set for Oct. 20

AnaptysBio has announced the dates for post-trial briefings in its Delaware Chancery Court dispute with Tesaro and GlaxoSmithKline regarding a collaboration license. AnaptysBio is seeking a declaration that Tesaro materially breached the agreement and alleges GlaxoSmithKline tortiously interfered. The consolidated trial concluded in July …

Arrowstreet Capital Limited Partnership Sells 67,624 Shares of AnaptysBio, Inc. $ANAB

Arrowstreet Capital Limited Partnership reduced its stake in AnaptysBio, Inc. by 12.1% in the first quarter, selling 67,624 shares and retaining 492,120 shares valued at approximately $27.3 million. AnaptysBio reported a significant quarterly loss per share of $1.84, missing analyst expectations, despite revenue exceeding …

ANAB|AnaptysBio Inc|Price:52.220|Chg%:+0.110

This article provides a comprehensive stock analysis of AnaptysBio Inc (ANAB) by TradingKey, highlighting its strong fundamentals and high growth potential. The company's valuation is considered fair within the Biotechnology & Medical Research industry, and it has received "Buy" ratings from multiple analysts. Despite …

AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for AnaptysBio Inc (ANAB), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 5.15, ranking 50 out of 384 in its industry, and a beta value of 0.89, indicating it tends …

AnaptysBio Inc (ANAB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of AnaptysBio Inc (ANAB), highlighting its current valuation score of 9.19 within the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -51.12, and indicates that P/B, P/S, and P/CF ratios have not yet been …

AnaptysBio (ANAB) Projected to Post Earnings on Wednesday

AnaptysBio (ANAB) is expected to announce its Q2 2026 earnings before market open on Wednesday, August 5th, with analysts projecting a loss of $0.1252 per share and revenue of $17.3340 million. The company missed earnings estimates in the previous quarter but exceeded revenue forecasts. …

AnaptysBio shifts to royalty management, focusing on growing Jemperli royalties from GSK.

AnaptysBio has transitioned into a royalty management company, concentrating on Jemperli, an oncology drug commercialized by GSK, after eliminating R&D expenses. The company aims for a 95% EBIT margin with over $140 million in net cash, anticipating increased Jemperli royalties and benefiting from high-margin …

Eversept Partners LP Decreases Stock Position in AnaptysBio, Inc. $ANAB

Eversept Partners LP significantly reduced its stake in AnaptysBio, Inc. by 77.6% in the first quarter, selling over 93,000 shares and retaining a smaller position valued at $1.5 million. This move comes despite AnaptysBio reporting revenue that exceeded analyst expectations, though it missed on …

AnaptysBio Inc (ANAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of AnaptysBio Inc (ANAB), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock is currently trading between resistance at $66.44 and support at $45.24, suitable for range-bound swing trading. …

AnaptysBio Inc (ANAB) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of AnaptysBio Inc's (ANAB) shareholder structure, listing major shareholders by proportion, categorizing shareholders by type, and detailing institutional shareholding data over several quarters. It also includes information on shareholder activity and related ETFs.

AnaptysBio, Inc. Revenue Breakdown – NASDAQ:ANAB

ANAB Cash Flow Statement

This article provides the quarterly and annual cash flow statements for AnaptysBio Inc (ANAB), detailing operating, investing, and financing cash flows from FY2015Q1 to FY2026Q1. It includes specific figures for net income, capital expenditures, and free cash flow, along with year-over-year changes. The document …

AnaptysBio, Inc. $ANAB Shares Sold by Granahan Investment Management LLC

Hsbc Holdings PLC Buys New Shares in AnaptysBio, Inc. $ANAB

HSBC Holdings PLC has acquired a new stake in AnaptysBio, Inc., purchasing 125,717 shares valued at approximately $7.1 million, representing about 0.43% of the company. This comes despite AnaptysBio reporting a larger-than-expected quarterly loss, though revenue exceeded estimates. Analysts maintain a "Moderate Buy" rating …

AnaptysBio, Inc.'s Equity Buyback announced on March 24, 2025 has expired with 3,444,079 shares, representing 11.5% for $68.63 million.

AnaptysBio, Inc.'s equity buyback program, which was announced on March 24, 2025, has concluded. The company repurchased 3,444,079 shares, accounting for 11.5% of its equity, at a total cost of $68.63 million. The plan officially expired on March 31, 2026.

AnaptysBio (NASDAQ:ANAB) Trading Up 5.6% - Here's What Happened

AnaptysBio (NASDAQ:ANAB) stock rose 5.6% on Thursday, trading as high as $55.94 with closing near $55.57, though with trading volume significantly lower than average. Analyst sentiment is mixed, leaning positive, with a consensus "Moderate Buy" rating and a price target of $81.82, despite recent …

H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95

H.C. Wainwright has reiterated its Buy rating for AnaptysBio (ANAB.US) and maintained its target price at $95. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial?

AnaptysBio (ANAB) is drawing attention due to potential royalty income from the cancer drug Jemperli and an upcoming trial with GSK, contributing to significant long-term share price gains despite recent volatility. With analysts suggesting a fair value of $90 against a current price of …

Barclays Keeps Their Buy Rating on AnaptysBio (ANAB)

ANAB Forecast — Price Target — Prediction for 2027

AnaptysBio Shifts Fiscal Year-End As Volatile Stock Eyes Growth Forecasts

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

AnaptysBio stock: UBS reiterates Buy rating amid ongoing GSK litigation

GSK, Anaptysbio sue each other over Jemperli revenue

What is the current Price Target and Forecast for AnaptysBio (ANAB)